LQLing Qiang

Ling Qiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Qiang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Guohua Ren

    Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China

    2 shared publications
  • Qiuyue Liu

    The Fourth People’s Hospital of Jinan, Jinan, People’s Republic of China

    2 shared publications
  • Shu Fang

    Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China

    2 shared publications
  • Dandan Xu

    Internal Medicine II, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan, China

    1 shared publication
  • Guohua Ren

    Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China

    1 shared publication
  • Shu Fang

    Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Correction: Real-time survival assessment in breast cancer with liver metastasis

    by Shu Fang, Guohua Ren, Qiuyue Liu, Ling Qiang

  • Open Access

    Real-time survival assessment in breast cancer with liver metastasis

    by Shu Fang, Guohua Ren, Qiuyue Liu, Ling Qiang

    Background The heterogeneity in outcomes of breast cancer liver metastasis (BCLM) complicates prognosis assessment. This study conducted conditional survival (CS) analysis and develop a CS-nomogram model for BCLM using SEER database data, providing individualized and adaptive prognostic predictions. Methods Data were extracted from the SEER 18 database, encompassing clinical records of BCLM patients diagnosed between 2010 and 2021. CS was calculated using the formula CS(t∣s) = S(t + s)/S(s), allowing for the dynamic assessment of survival probabilities. Annual hazard rate (AHR) analysis was performed to evaluate the risk of mortality at specific time intervals. A two-stage feature selection process was used to identify prognostic factors. We then developed a CS-nomogram, validated through calibration curves, time-dependent receiver operating characteristic curve (ROC) analysis, and decision curve analysis (DCA). Results The study cohort comprised 4,702 BCLM patients. The CS analysis and AHR analysis demonstrated that survival probabilities improved progressively for patients who survived beyond the high-risk period, particularly during the first year post-diagnosis. The CS-nomogram, developed using Cox regression, incorporated 14 variables, including patient characteristics, tumor features, and treatment information. It effectively predicted overall survival and CS at 3, 5, and 10 years. The model’s clinical utility was confirmed through calibrations, ROC with area under the curve values, and DCA, offering valuable insights for individualized treatment decisions. Conclusion By incorporating CS analysis, this study provided a dynamic, adaptable approach to predict prognosis for BCLMs. The CS-nomogram model transformed survival probabilities into a continuously adjustable process, supporting more precise clinical decision-making and offering hope to patients with a historically poor prognosis.


  • Open Access

    Molecular Characteristics, Clinical Implication, and Cancer Immunity Interactions of Pyroptosis-Related Genes in Breast Cancer

    by Dandan Xu, Zhipeng Ji, Ling Qiang

    Objective: Pyroptosis represents an emerging inflammatory form of programmed cell death. Herein, specific functions and clinical implications of pyroptosis-related genes were systematically characterized in breast cancer.Methods: Expression, somatic mutation and copy number variation of 33 pyroptosis-related genes were assessed in breast cancer from TCGA dataset. Their interactions, biological functions and prognostic values were then observed. By stepwise Cox regression analysis, a pyroptosis-related gene signature was generated. The predictive efficacy in survival was examined by survival analyses, ROCs, univariate and multivariate analyses and subgroup analyses. Associations between risk score (RS) and cancer immunity cycle, HLA, immune cell infiltrations, and immune checkpoints were analyzed.Results: Most of pyroptosis-related genes were abnormally expressed in breast cancer. CASP8, NLRC4, NLRP3, NLRP2, PLCG1, NLRP1, NLRP7, SCAF11, GSDMC, and NOD1 occurred somatic mutations as well as most of them had high frequency of CNV. There were closely interactions between them. These genes were distinctly enriched in immune-related processes. A three-gene signature was generated, containing IL-18, GSDMC, and TIRAP. High RS predicted poorer overall survival, progression, and recurrence. After verification, this RS was an independent and sensitive predictive index. This RS was negatively correlated to cancer immunity cycle. Also, low RS was characterized by high HLA, immune cell infiltrations and immune checkpoints. A nomogram including age and RS was generated for accurately predicting 5-, 8-, and 10-year survival probabilities.Conclusion: Pyroptosis-related genes exert key roles in cancer immunity and might be applied as a prognostic factor of breast cancer.